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In vitro production of Klotho protein for analysis of Alzheimer’s human brain samples 
ABSTRACT 
Klotho protein is a neuroprotective factor related to aging and Alzheimer’s disease (AD). The 
secreted variant (s-KL) of the protein, which is the most expressed variant in humans, seems to 
have an important role in the maintenance of cognitive functions. Hence, the study of s-KL in 
humans is of high relevance for understanding its implications in AD and aging. In this work, the 
cDNA of the human s-KL protein was cloned in a eukaryote expression vector. s-KL protein was 
then produced by transient transfection in the HEK-293 human cell line, whose protein extracts 
were quantified and analysed by Western Blot. Immunodetection of s-KL was carried out through 
a specific antibody (K-18.2) never used before, for which a new protocol was developed as well. 
This assay allowed us to evaluate the production of s-KL by the transfected cells, as well as the 
specificity of the new K-18.2 antibody. Finally, a complementary validation of K-18.2 using 
protein extracts from human brains, obtained from both healthy and AD patients, was conducted.  
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Producción in vitro de la proteína Klotho para el análisis de muestras humanas de 
cerebros de Alzheimer 
RESUMEN 
La proteína Klotho es un factor neuroprotector relacionado con el envejecimiento y la enfermedad 
de Alzheimer (AD, del inglés Alzheimer’s disease). La variante secretada de la proteína (s-KL), 
que es la más expresada en humanos, parece tener un papel importante en el mantenimiento de 
las funciones cognitivas. Por ello, el estudio de la variante s-KL en humanos es de gran relevancia 
para poder entender su implicación en el AD y el envejecimiento. En este trabajo, el cDNA de la 
proteína s-KL humana fue clonado en un vector de expresión eucariota. Después, la proteína  
s-KL fue producida por transfección transitoria en la línea celular humana HEK-293, cuyos 
extractos proteicos fueron cuantificados y analizados por Western Blot. La inmunodetección de 
s-KL se llevó a cabo mediante un anticuerpo específico (K-18.2) nunca antes utilizado, y para el 
cual se desarrolló también un protocolo. Este ensayo permitió evaluar la producción de s-KL por 
las células transfectadas y la especificidad del nuevo anticuerpo K-18.2. Finalmente, se llevó a 
cabo una validación complementaria del anticuerpo K-18.2, utilizando extractos proteicos de 
cerebros humanos, obtenidos de pacientes sanos y enfermos de AD. 
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Producció in vitro de la proteïna Klotho per a l’anàlisi de mostres humanes de cervells  
d’Alzheimer 
RESUM 
La proteïna Klotho és un factor neuroprotector rel·lacionat amb l’envelliment i la malaltia 
d’Alzheimer (AD, de l’anglés Alzheimer’s disease). La variant secretada de la proteïna (s-KL), la 
més expressada en humans, sembla tindre un paper important en el manteniment de les funcions 
cognitives. És per això que l’estudi de la variant s-KL en humans és de gran rellevància per poder 
entendre la seua implicació en l’AD i l’envelliment. En aquest treball, el cDNA de la proteïna  
s-KL humana va ser clonat en un vector d’expressió eucariota. Després, la proteïna s-KL fou 
produïda per transfecció transitòria en la línia cel·lular humana HEK-293, i els seus extractes 
proteics foren quantificats i analitzats per Western Blot. La immunodetecció de s-KL es va 
realitzar mitjançant un anticòs específic (K-18.2) mai abans utilitzat, i per al qual es va 
desenvolupar un nou protocol. Aquest assaig va permetre avaluar la producció de s-KL per les 
cèl·lules transfectades i la especificitat del nou anticòs K-18.2. Finalment, es va portar a terme 
una validació complementaria de l’anticòs K-18.2 utilitzant extractes proteics de cervells humans, 
obtinguts de pacients sans i malalts d’AD.  
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1. INTRODUCTION 
 Alzheimer’s disease  
Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases, involving the 
progressive loss of mental, behavioural, functional decline and ability to learn (Anand, Gill, & 
Mahdi, 2014). AD accounts for more than 80% of dementia cases, and has become a leading cause 
of death and disability in aged people worldwide (Kumar, Singh, & Ekavali, 2015). One person 
for every 85 individuals can be expected to suffer from AD by the year 2050 (Brookmeyer, 
Johnson, Ziegler-Graham, & Arrighi, 2007). However, the pathogenesis of AD is not yet fully 
understood (Kuang et al., 2014).  
Etiology of AD is multifactorial with genetic, environmental, behavioural and developmental 
components playing role (Anand et al., 2014). Several hypotheses have been proposed to explain 
the pathophysiology of AD. They include: 
 Aberrant β-amyloid (Aβ) metabolism, giving rise to Aβ extracellular plaques. 
 Hyperphosphorylation of cytoskeletal proteins like tau, causing intraneuronal deposits. 
 Mutations in genes coding for presenilin-1 and -2 (PSEN1 and PSEN2, respectively) and 
amyloid precursor protein (APP). 
 Apolipoprotein E genotype. 
 Oxidative stress. 
 Excitotoxicity. 
 Inflammation. 
 Abnormal cell cycle re-entry. 
However, none of these hypotheses alone is sufficient to explain the different biochemical and 
pathological abnormalities in AD (Kumar & Dogra, 2008). Despite the diversity of the 
mechanisms involved, neuronal death is the inevitable event resulting in AD (Anand et al., 2014). 
It is commonly accepted that the causes 
leading up to memory decline are strongly 
tied to deposits of misfolded protein 
aggregates (Ross & Poirier, 2004).  
Beta-amyloid (Aβ) plaques and 
neurofibrillary tangles (NFTs) are the 
hallmark deposits in AD brains (Lewczuk, 
Mroczko, Fagan, & Kornhuber, 2015)  
(Figure 1). These aggregates derive from the 
naturally occurring and crucial protein 
structures in the brain Aβ and tau (Muresan 
& Ladescu Muresan, 2015; Nhan, Chiang, & 
Koo, 2015). However, their abnormal 
aggregation causes progressive neuronal 
death, memory impairment, and cognitive 
disturbances (Tanzi & Bertram, 2005). 
 
 
Figure 1. Protein aggregates in an Alzheimer’s 
diseased brain. 
Neurofibrillary tangles of tau and amyloid 
plaques of Aβ accumulate inside neurons and 
in the extracellular space, respectively. 
Adapted from BrightFocus Foundation (2016). 
Retrieved September 2016 from 
http://www.brightfocus.org/alzheimers/infographi
c/amyloid-plaques-and-neurofibrillary-tangles.      
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1.1.1. Protein deposits behind AD: Aβ and tau 
Aβ plaques 
Recent studies highlight the role of Aβ oligomers in synaptic impairment, suggesting that these 
are primarily the only one among several other signals that destroy the integrity of brain 
functions (Anand et al., 2014).  
Aβ derive from the amyloid precursor protein (APP), which is a type I membrane glycoprotein 
having multiple isoforms generated by alternative splicing. However, physiological functions of 
APP are poorly understood (Müller & Zheng, 2012). There are two proteolytic processing 
pathways of APP, as shown in Figure 2. In the non-amyloidogenic pathway, APP is cleaved by 
α-secretases, resulting in the production of the soluble form of APP (sAPPα), which has several 
neuroprotective properties. In the amyloidogenic pathway, APP is aberrantly processed by  
β-secretases, generating a membrane-bound C-terminal fragment (C99), which is subsequently 
cleaved by γ-secretases. As a result, the Aβ peptide is generated (Nunan & Small, 2000), causing 
an imbalance between production and clearance of Aβ peptide (Salomone, Caraci, Leggio, 
Fedotova, & Drago, 2012). As a consequence, Aβ peptides spontaneously aggregate into soluble 
oligomers and join each other to form insoluble fibrils of beta-sheet conformation, which are 
eventually deposited in diffuse senile plaques (Hardy, 2009). It has been observed that Aβ 
oligomers induce oxidative damage, promote tau hyperphosphorylation, and result in toxic 
effects on synapses and mitochondria (Kumar & Dogra, 2008). In short, Aβ oligomers 
aggregates are considered to be responsible for the neuronal and vascular degeneration in AD 
brains (Roth, Ramírez, Alarcón, & Von Bernhardi, 2005).  
 
Figure 2. Proteolytic processing pathways of APP: non-amiloidogenic (left) or amyloidogenic (right). 
Hyperphosphorylated tau 
Tau proteins are mainly found in neurons and belong to the family of microtubule-associated 
proteins (Tucker, 1990). Six isoforms of tau proteins identified in the adult brain play an 
important role in microtubule assembly and stabilization of neuronal microtubules network (Lee, 
Neve, & Kosik, 1989). The phosphorylation of tau protein is developmentally regulated from 
foetal to adult stage (Butler & Shelanski, 1986). However, when abnormally 
hyperphosphorylated, tau has a reduced affinity towards microtubules (Mazanetz & Fischer, 
2007). The hyperphosphorylated tau proteins polymerized into paired helical filaments (PHF) 
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and straight filaments (SF) are referred to as neurofibrillary tangles (NFTs) (Köpke et al., 1993). 
The loss of normal tau function leads to a pathological disturbance in structural and regulatory 
functions of the cytoskeleton, which affect normal cellular functions of neurons, for instance the 
maintenance of appropriate morphology and the axonal transport, causing synaptic dysfunction 
and neurodegeneration (Roy, Zhang, Lee, & Trojanowski, 2005).  
1.1.2. AD treatments and its major risk factor, age 
The multiplicity of mechanisms involved in the pathogenesis of AD make difficult to develop 
an effective treatment for AD (Anand et al., 2014). To date, approved drugs just slow disease 
progression, reduce problematic behaviours or alleviate cognitive symptoms, but do not alter the 
course of the disease. In addition, these therapies only show efficacy in a reduced number of 
patients, for a short period of time, and undesirable side effects are frequently observed. Thus, 
further research is needed to fully understand Alzheimer’s etiology, improve its early diagnosis 
and develop effective drugs capable of block or completely cure the disease.  
The major risk factor for AD is age, with a sharp increase in incidence after 60 years (Kawas et 
al., 2000). This is why many researchers agree that in order to understand AD, we must 
understand its inherent relationship to aging (Herrup, 2010). With the growing longevity of 
population in the last decades, AD prevalence has highly increased, and it is already reaching 
epidemic proportions with no cure or preventive therapy yet available (Tanzi & Bertram, 2005).  
The progressive loss of both cognitive functions and the ability to form new memories that 
occurs associated to neurodegenerative diseases like AD is known as dementia, and it must not 
be understood as the memory loss associated to aging, in which the intellectual and behavioural 
functions of the person work correctly. In other words, dementia is not a part of the normal 
process of aging, but is considered a pathology, being AD the most important type. However, 
both pathological and non-pathological processes could be associated to common factors, for 
instance the IGF-1 pathway, in which the Klotho (KL) protein is involved. This protein has been 
associated with the maintenance of cognitive functions, so it has become a promising research 
line to better understand the neurodegeneration related to both AD and non-pathological aging.  
 Klotho 
The Klotho gene, named after the Greek goddess who spins the thread of life, was discovered in 
1997, when its mutation caused systemic aging and shortened longevity in mice (Kuro-o et al., 
1997). The aging phenotypes included impaired cognition, arteriosclerosis, decreased bone 
mineral density, and sarcopenia (Kuro-O, 2010). Conversely, overexpression of klotho extended 
the life span in mice (Kurosu et al., 2005), which supports the perception of klotho as an aging-
suppressor gene.  
The expression of klotho is specific to certain tissues including kidney, brain and the parathyroid 
gland. In the brain, klotho is highly expressed in the ependymal cells of the choroid plexus and in 
Purkinje EC cells, as well as in hippocampal neurons (Kuro-o et al., 1997). Recently, both Klotho 
mRNA and protein were detected throughout the brain parenchyma, co-localizing in neurons and 
oligodendrocytes during early postnatal development (Clinton et al., 2013). This suggests that 
Klotho protein may influence a variety of structures and functions during the central nervous 
system (CNS) maturation and aging.  
Klotho-deficient mice (kl-/kl-) have fewer dopaminergic neurons (Kosakai et al., 2011), neuronal 
degeneration in the hippocampus (Shiozaki et al., 2008), hypomyelination (Chen et al., 2013), 
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fewer synapses and lower synapse-related protein levels compared to wild-type mice  (Li et al., 
2004; Shiozaki et al., 2008). In addition, they show deficient axonal transport (Uchida et al., 
2001). Behavioral studies also indicate that kl-/kl- mice have deficits in memory retention (Nagai 
et al., 2003), probably due to an increase in the oxidative stress in the brain.  
In contrast, mice overexpressing klotho perform better in Morris Water-Maze tests (Nagai et al., 
2003), which evaluate hippocampus-dependent spatial memory and learning. In other studies, it 
was observed that overexpression of klotho extends life by attenuating generation of reactive 
oxygen species evoked by insulin and IGF-1 signaling (Kurosu et al., 2005; Yamamoto et al., 
2005). Wnt, TNFα and IFNγ signaling are augmented in Klotho-deficient mice, which contribute 
to accelerated aging (Liu et al., 2007).  
Apart from that, recent studies in humans cohorts showed that carriers of the Klotho KL-VS allele, 
which increases secretion of Klotho in vitro, obtained better results in various cognitive tests, 
including verbal capacity, executive function, visual-spatial processing, and learning (Dubal et 
al., 2014). A meta-analysis of the KL-VS variant indicated that it is associated with healthy aging 
(Di Bona, Accardi, Virruso, Candore, & Caruso, 2014).  
1.2.1.  Klotho gene and protein structure 
In mice and humans, the klotho gene is composed of five exons and encodes a transcript of 5.2 
kb. In the third exon, there is an alternative splicing donor site that can generate two different 
transcripts (Matsumura et al., 1998; Shiraki-Iida et al., 1998). 
The full-length transcript encodes a single pass transmembrane protein (1014 and 1012 amino 
acids in mouse and human, respectively) with a molecular weight of approximately 130kDa  
(m-KL). The intracellular domain is very short (~10 amino acids), and it does not have 
functional domains. The extracellular domain has two internal repeats, KL1 and KL2, linked by 
a region containing four basic amino acids (Lys-Lys-Arg-Lys) that form a potential site for 
proteolytic cleavage (Kim, Hwang, Park, Kong, & Cha, 2015). Membrane proteases such as 
ADAM10 and ADAM17 (ADAM metalloproteinase domain 10 and 17, respectively) cleave the 
extracellular domain of Klotho in this site, generating the so called cleaved or processed Klotho 
(p-KL), which is released into blood, urine and cerebrospinal fluid (Bloch et al., 2009), and 
functions as an endocrine, autocrine and paracrine hormone on target cells (Kuro-o et al., 1997; 
Kurosu et al., 2005).   
The transcript generated by alternative splicing is composed of 3 exons in mouse and 5 exons in 
human. It encodes the secreted form of the protein (s-KL), also called truncated transcript, 
which is formed solely by the KL1 domain (composed of 549 and 550 amino acids in mouse 
and human, respectively), with an approximate weight of 70kDa. This secreted form of the 
protein contains an exclusive peptide tail at C-terminus (15 amino acids for murine s-KL, and 
16 amino acids for human s-KL), which is not present in the transmembrane nor in the processed 
forms  (Xu & Sun, 2015).  
In mice, the transmembrane form of klotho transcript (m-KL) predominates over the secreted 
form (s-KL), while in humans, the s-KL is the most expressed. 
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Figure 3. Schematic structures of Klotho gene, mRNA and protein variants. The resultant alternatively 
spliced transcript contains 50bp insertion after exon 3, represented in grey.  The exclusive peptide tail 
at C-terminus of s-KL is marked in purple. Extracellular domain of membrane Klotho (m-KL) containing 
KL1 and KL2 repeats is cleaved by α- and β-secretases (ADAM10 and ADAM17), represented in red. 
Adapted from Hu, Kuro-o, & Moe, 2012. 
1.2.2.    Molecular functions of Klotho 
Processed (p-KL) and secreted Klotho (s-KL) are referred to as soluble klotho, as they are both 
released into body fluids - blood, urine and cerebrospinal fluid (CSF) - being s-KL the major 
form of soluble Klotho. However, no previous studies have evaluated the particular properties 
of each soluble variant separately. This is due to the fact that, to date, all the commercial 
antibodies are directed to the common domain KL1, so they are not capable to discriminate 
between p-KL and s-KL. Hence, the discovered functions of the soluble Klotho have been 
attributed to both variants.  
Soluble Klotho works as a humoral factor that targets multiple tissues and organs. It exerts 
pleiotropic activities including regulation of oxidative stress, growth factor signaling, and ion 
homeostasis. In addition, soluble Klotho is involved in organ protection and has anti-aging 
effects. Soluble Klotho has direct effects on tissues and cells that do not express Klotho, which 
partially explains why a mutation in the klotho gene causes such extensive aging phenotypes. 
Therefore, Klotho may function as a hormone, although the binding sites or the receptors for 
Klotho remain unknown (Xu & Sun, 2015). Hence, it would be important to identify and 
characterize Klotho receptors and investigate its downstream signaling in future studies. Apart 
from this, it was reported that circulating levels of soluble Klotho decrease with age, and the 
klotho gene is associated with increased risk of age-related diseases (Kim et al., 2015). 
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Below, we summarize the main molecular functions in which the transmembrane and the soluble 
forms of Klotho seem to be implicated.  
 Inhibition of the insulin/IGF-1 signaling pathway 
Several studies have reported that disruption of Klotho expression decreases insulin production 
and increases insulin sensitivity (Utsugi et al., 2000). Klotho knockout mice also exhibit less 
energy storage and less energy expenditure compared with wild-type mice (Mori et al., 2000). 
Several studies have shown that Klotho suppresses the downstream signaling pathway of the 
insulin receptor substrate (IRS) and the IGF-1 receptor (IGF-1R) without directly binding to 
these receptors (Kurosu et al., 2005). Therefore, Klotho may indirectly regulate the insulin/IGF 
signaling pathway (Wang & Sun, 2009), although the exact mechanism remains to be 
elucidated. 
 Suppression of WNT signaling 
It was reported that Klotho binds to different types of Wnt ligands to suppress the downstream 
signaling transduction, and also that Klotho knockout increases Wnt signaling in mice (Liu et 
al., 2007). The activated Wnt3 signaling pathway prolongs the cell cycle by arresting it at the 
G2/M phase and up-regulating fibrogenic cytokines. Conversely, the Klotho treated cells 
bypass this phase and exhibit reduced fibrogenic cytokines production (Satoh et al., 2012). 
Hence, Klotho may suppresses the Wnt signaling, so it could also possess anti-cancer and 
antioxidative properties.  
 Participation in Ca2+ homeostasis 
Soluble Klotho increases the abundance of cation channel TRPV5 on the cell membrane 
(Chang et al., 2005). In HEK-293 cells that are co-transfected with TRPV5 and klotho, calcium 
(Ca2+) uptake is increased in proportion to klotho expression (Asai et al., 2012). In a transgenic 
mouse model with targeted disruption of the klotho gene in the renal distal tubule, a decrease 
in TRPV5 expression in the distal tubular cells was accompanied by a mild increase in urinary 
calcium excretion (Olauson et al., 2012). Klotho may therefore regulate calcium metabolism 
via TRPV5. Nevertheless, no significant association between Klotho and TRPV5 expression 
has been found in the kidney yet. Some reports indicate that Klotho binds to vascular 
endothelial growth factor receptor-2 (VEGFR2) and transient-receptor potential canonical Ca2+ 
channel 1 (TRPC-1) through its KL2 domain, and regulates TRPC-1-mediated Ca2+ flux entry 
to maintain endothelial integrity (Kusaba et al., 2010). A recent study indicated that Klotho 
increases the plasma membrane retention of TRPV2, leading to enhanced glucose-induced 
insulin secretion in pancreatic β-cells (Lin & Sun, 2012). It will be of interest in future studies 
to assess how soluble Klotho regulates multiple ion channels and how the ion flux contributes 
to the aging process. 
 Participation in phosphate homeostasis and vitamin D metabolism 
Phosphate (Pi) is essential to a variety of physiological processes and is regulated by D vitamin 
(1,25(OH)2D3), the parathyroid hormone (PTH), and fibroblast growth factor 23 (FGF23) 
(Tanaka & Deluca, 1974).  Pi absorption increases the secretion of FGF23, a bone-derived 
hormone that is critical in the regulation of the renal excretion of Pi (Farrow, Imel, & White, 
2011). Secreted FGF23 has a low affinity to its receptors (FGFRs). Transmembrane Klotho 
binds to FGFRs to enhance the binding ability of FGF23. This binding activates a MAPK 
cascade, which inhibits Pi reabsorption in renal proximal tubule cells and suppresses the 
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expression Cyp27b1 gene that encodes 1-α-hydroxylase, which hydrolyzes 25-
dihydroxyvitamin D3 to generate 1,25(OH)2D3 (Kuro-o, 2006; Urakawa et al., 2006).   
 Suppression of oxidative stress 
FOXO3a up-regulates the expression of manganese superoxide dismutase (MnSOD), an 
important enzyme for mitochondrial antioxidant defences in mammalian cells (Kurosu et al., 
2005; Yamamoto et al., 2005). FOXO3a functions as a negative regulator of mitochondrial 
reactive oxygen species (ROS) generation. Klotho increases FOXO3a phosphorylation, 
suggesting that Klotho may suppress ROS-related oxidative stress. Klotho overexpression 
decreases H2O2-induced apoptosis, β-galactosidase activity, mitochondrial DNA 
fragmentation, superoxide anion generation, lipid peroxidation, and Bax protein expression 
(Wang, Kuro-O, & Sun, 2012). Although the mechanism by which Klotho extends the cellular 
life span is not fully understood, a recent study indicates that low levels of ROS-related stress 
responses are beneficial to the organism and can extend the life span of a cell (Sena & Chandel, 
2012). This result suggests that the anti-aging function of Klotho may involve ROS and its 
downstream signaling pathways. 
In conclusion, the discovered functions of Klotho point out that this protein plays an important 
role in neurodegenerative and age-related diseases.   
 
Figure 4. Overview of the functions of Klotho. (a) Klotho inhibits the IGF signaling pathway. The 
downstream factors FOXO1, -3a, and -4 mediate the function of Klotho. (b) Klotho suppresses the Wnt 
signaling pathway. (c) Klotho regulates TRPV5 calcium channels. (d) Klotho regulates PTH synthesis. (e) 
The Klotho-FGF23 complex regulates Pi absorption, mineral metabolism, and vitamin D3 expression and 
activity. Adapted from Xu & Sun, 2015.  
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 Previous studies relating Klotho, AD and aging 
Klotho is a neuroprotective factor, as demonstrated in vitro on hippocampal neurons against 
glutamate and beta-amyloid peptide (Aβ) cytotoxicity through an increased resistance to oxidative 
stress (Zeldich et al., 2014). Klotho was also able to counteract cognitive deficits and premature 
mortality in human amyloid precursor protein (hAPP) transgenic mice J20, a well-characterized 
animal model of Alzheimer’s disease (Dubal et al., 2015). In addition, Klotho is a synaptic 
modulator that increases the expression of acetylcholine transferase, whose continued activity 
diminution has been correlated with an increase in cognitive deficits ((Bohnen et al., 2005).  
It was suggested that Klotho might prevent the development of AD associated with aging, 
probably by inhibiting insulin/IGF-1 signaling and consequently the oxidative injury in the brain. 
However, no previous studies had directly connected Klotho and the AD phenotype until 2014, 
when Semba et al. analyzed Klotho in the CSF of older adults with Alzheimer's disease and in 
older and younger adults with normal cognition. They concluded that Klotho concentrations in 
the CSF were significantly lower in older adults with Alzheimer's disease compared to older 
adults with normal cognition. They also reported that Klotho levels were lower in CSF of older 
adults compared to younger adults (Semba et al., 2014). Even though this study revealed a 
connection between diminished levels of soluble Klotho and AD and aging, it did not 
specify whether these variations correspond to the processed (p-KL) or to the secreted (s-KL) 
form of the protein. This is due to the fact that, thus far, all the commercial antibodies available 
recognize an epitope located in the KL1 domain, which is common in all Klotho forms, as 
previously explained. Thus, the antibodies used were not able to discriminate s-KL from the KL1 
domain cleaved from the transmembrane isoform (p-KL). 
In order to overcome this limitation, our group generated a new antibody (Ab-K113) against the 
exclusive peptide tail at the C-terminus of the s-KL protein in mice. This antibody was used to 
detect s-KL in different brain areas of young (6-month-old) and old adult mice (18-month-old). 
They observed that the levels of s-KL protein declined with aging in all brain areas analyzed, but 
in the cerebellum, in which s-KL levels were similar at both ages. It should be noted that this was 
the first time that the levels of the alternatively spliced secreted Klotho protein (s-KL) were 
specifically quantified without interference from the KL1 or KL1+KL2 domains produced after 
cleavage of the transmembrane Klotho protein (Massó et al., 2015).  
Apart from that, our team analyzed the expression profiles of both transmembrane (m-KL) and 
secreted (s-KL) Klotho in kidney and brain, the organs in which it is more expressed. It turned 
out that expression levels of the two Klotho transcripts decayed with age in both organs. It was 
also observed that in mouse kidney, the expression of m-KL was higher than that of s-KL, as 
previously described by other groups (Bektas et al., 2004). Likewise, the expression of m-KL in 
the brain was also higher than that of s-KL.  
Given the structural and functional heterogeneity of the brain, our team studied whether the 
reduced expression of klotho associated with aging was uniform throughout this organ or was 
more pronounced in some areas than in others. They observed that in all the brain areas analyzed, 
the expression of both klotho transcripts decayed with aging. Moreover, this decay was not 
uniform throughout the brain, and the decay of s-KL had a different profile to that of m-KL. This 
suggested a different regulation of their expression, and/or possible different roles for s-KL and 
m-KL protein variants. 
Apart from this, our group analyzed whether the reduction observed in the expression of the s-KL 
and m-KL transcripts in the different brain areas during non-pathological aging was also observed 
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in pathological aging, as happens in neurodegenerative disorders like Alzheimer's disease. They 
analyzed the expression profile of the s-KL and m-KL transcripts in different brain areas of 6-,  
9-, and 12-month-old 3xTg-AD mice, a suitable animal model for Alzheimer’s disease. As 
observed in non-pathological aging, the expression of both transcripts declined rapidly, but in the 
3xTg-AD transgenic model of Alzheimer’s disease, klotho decayed more rapidly compared to 
healthy animals of the same age. However, during aging, differences in the expression profile of 
s-KL and m-KL were reduced, and at 12 months of age, s-KL and m-KL levels were similar in 
3xTg-AD and control mice.  
As observed for s-KL mRNA expression, levels of the s-KL protein were also lower in 3xTg-AD 
mice. Thus, compared with healthy aged-matched controls, s-KL protein levels were reduced at 
6 and 12 months of age. In other words, s-KL levels in 3xTg-AD mice were low even before 
symptoms like amyloidogenic plaques appeared, what enhances its potential as an early biomarker 
of AD.  
In short, the research of Massó et al. showed for the first time that the klotho transcript produced 
by alternative splicing generates a stable protein (s-KL) of 70kDa, and that in contrast to the 
transmembrane Klotho isoform (m-KL), it is ten times more abundant in the brain than in the 
kidney. They also demonstrated that s-KL and m-KL have different expression profiles and 
localization, suggesting that the different forms of Klotho protein have different regulation of 
their expression, and/or possible different roles. 
Given that s-KL is highly expressed in brain and it has a neuroprotective role, it seems that s-KL 
has a crucial role in key areas for cognitive function, which are targets of study in both aging and 
neurodegenerative diseases. This, together with the fact that the s-KL isoform is the most 
expressed in humans (Shiraki-Iida et al., 1998) - in contrast to mice, in which the m-KL is more 
abundant -, could indicate that the s-KL isoform is even more relevant in humans. 
Thus, we focused our research in the human s-KL protein variant in order to elucidate the way in 
which its deficiency leads to the decline of cognitive functions associated to aging and 
Alzheimer’s disease. To this end, our group generated a new antibody (K-18.2) specific for the 
human form of s-KL, since its exclusive tail is not homologue to that of the murine s-KL, for 
which the K113 antibody had previously been produced and was available at our laboratory.  
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2. OBJECTIVES AND WORKFLOW  
The aim of this work is to clone the cDNA of the human secreted form of Klotho protein (human 
s-KL, hereafter named hKLS) into a eukaryote expression vector, and to transfect it into the 
human cell line HEK-293. The in vitro produced hKLS protein would be used for two different 
and complementary approaches: 
 On the one hand, to validate the new K-18.2 antibody, specifically designed by our group 
to detect the hKLS protein.  
 On the other hand, to build a calibration curve which allows the relative quantification of 
hKLS in human samples.  
Having these tools optimized, the future goal will be to analyse the hKLS protein in human 
samples of healthy and AD patients, and to correlate its levels with the progression and severity 
of the disease.  
Workflow: 
1. Amplification of the hKLS cDNA 
1.1. Transformation of competent E.coli bacteria using the synthetic pEX+hKLS plasmid. 
1.2. Pre-culture of transformed colony. 
1.3. DNA minipreparation of the pre-cultured colony. 
1.4. Verification of the transformation by enzymatic DNA digestion. 
1.5. DNA maxipreparation of the transformed colony.  
2. Cloning the hKLS cDNA into an eukaryote expression vector (pGV) 
2.1. Enzymatic digestions of pEX-hKLS amplified plasmid and the pGV acceptor vector.  
2.2. Separation of DNA fragments by electrophoresis in agarose gel. 
2.3. Purification of the hKLS insert and the linealized pGV vector from gel. 
2.4. Dephosphorilation of the linealized pGV ends. 
2.5. DNA quantification. 
2.6. Ligation of the hKLS insert to the pGV vector. 
3. Verification of the ligation 
3.1. Transformation of competent E.coli bacteria using the expression vector pGV+hKLS. 
3.2. Selection and pre-culture of transformed bacteria. 
3.3. DNA minipreparations. 
3.4. Verification of the ligation by enzymatic DNA digestions and electrophoresis. 
3.5. Amplification of the positive ligation by maxipreparation. 
3.6. DNA quantification. 
3.7. Verification of the amplified colony by enzymatic DNA digestions and electrophoresis. 
4. In vitro production of the hKLS protein  
4.1. Transfection of HEK-293 cells using the pGV+hKLS expression vector. 
4.2. Protein extraction. 
4.3. Protein quantification by spectrophotometry.  
5. hKLS protein analysis by Western Blot 
5.1. Optimization of K-18.2 antibody protocol using protein extracts from mice. 
5.2. Denaturing protein electrophoresis (SDS-PAGE). 
5.3. Electrotransference. 
5.4. Immunodetection of hKLS using the K-18.2 antibody. 
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3. MATERIALS and METHODS  
 Bacterial strains 
Chemically competent bacteria were produced in our laboratory using E.coli TOP10R (Invitrogen) 
strain. Competent bacteria are able to incorporate exogenous DNA, and were used to amplify 
plasmidic DNA smaller than 10kb.  
 In vitro cell lines  
Human embryonic kidney cell line, HEK-293 QB (ATCC® CRL-573TM, Q-BIOgene) was 
propagated in Dulbecco’s Modified Eagle’s Medium (DMEM) (PAA laboratories) supplemented 
with 10% v/v Fetal Bovine Serum (FBS) (PAA laboratories) and Penicillin (100 
I.U/ml)/Streptomycin (100 I.U/ml) (PAA Laboratories) at 37oC and 5% CO2.  
DNA constructs 
pEX+hKLS plasmid 
The gene coding the human secreted Klotho protein (hKLS) was designed by our group and 
ordered to Eurofins Genomics (Ebersberg, Germany) in the pEX-K4 plasmid (KanR). 
pGV vector 
The kKLS gene was cloned in the mammalian expression vector pGV (AmpR) under the control 
of the cytomegalovirus (CMV) promoter, obtaining de pGV+hKLS construct. This plasmidic 
pGV vector was generated in our laboratory.  
pDsRed2-Mito Vector 
pDsRed2-Mito (Conda), designed for fluorescent labeling of mitochondria, is highly expressed 
in mammalian cells. It encodes a fusion of Discosoma sp. red fluorescent protein (DsRed2) and 
a mitochondrial targeting sequence of human cytochrome c oxidase subunit VIII (Mito). 
pDsRed2-Mito Vector (AmpR) was used as a positive control in the transfection experiments.  
 Murine samples 
Murine brain samples were obtained from 12 month old, C57Bl6 male mice (Harlan Laboratories 
BV), which exhibit a wild type phenotype.  
 Human samples 
Human brain samples were provided by Dr. Isidre Ferrer, from the biobanc of the Hospital del 
Bellvitge. Brain samples were obtained from deceased donors, both healthy and AD patients and 
kept at -80ºC.  
 Stock solutions 
The composition of the solutions and buffers prepared in our laboratory and used in the protocols 
is detailed below: 
DNA minipreparations 
 P1 or Resuspension buffer (4ºC): 50mM Tris-HCl (Sigma) pH=8.0, 10mM EDTA 
(USB), 100mg/mL RNasaA (QIAGEN). 
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 P2 or Lysis buffer (RT): 200mM NaOH (Panreac), 1% (w/v) SDS (Amresco).  
 P3 or protein precipitation buffer (4ºC, pH=5.5): 3M AcK (Sigma). 
DNA agarose gel electrophoresis 
 Loding buffer: 50% glicerol (v/v) (Sigma‐Aldrich), 100mM EDTA pH 8.0 (USB), 1% 
SDS (p/v) (Iberlabo), 0.1% (p/v) bromofenol blue or Xylene Cyanol FF.  
Bromophenol blue and Xylene Cyanol FF run toward the anode as 500bp and 4kb bands, 
respectively. The choice of one of them depends on the DNA fragment size we expect to 
separate. 
 TAE 1x (pH=8.0): 40mM Tris-acetic, 0.1mM EDTA. 
Transfection of cultured cells 
 PBS (phosphate buffered saline) (pH= 7.4): 137mM NaCl (Panreac), 3mM KCl 
(Panreac), 10mM Sodium Dihydrogen Phosphate Dodecahydrate (Panreac), 1.7mM 
Potassium dihydrogen phosphate (Panreac). 
Protein extraction  
 RIPA buffer: 50mM Tris‐HCl pH 7.4 (Sigma), 150mM NaCl (Panreac), 1mM EDTA 
(USB), 1% (v/v) NP‐40 (Fluka), 0.25% (v/v) Sodium Deoxycholate (Sigma), 50mM 
Sodium fluoride (Sigma), 1mM Sodium Orthovanadate (Sigma), 10mM  
Na-β-glycerophosphate (Sigma), 5mM pyrophosphate (Sigma), protease inhibitors 
(Roche). 
Western Blot   
 Acrylamide Bis-acrylamide solution (29:1) (Amresco). 
 Resolving gel buffer (pH=8.8): 1.5M Tris-HCl (Sigma), 0.4% SDS (USB). 
 Stacking gel buffer (pH = 6.8): 0.5M Tris-HCl, 0.4% SDS. 
 Loading buffer (5x): 20% glycerol (Panreac), 10% SDS, 0.32% 2-β-mercaptoethanol 
(Sigma), 0.02% bromophenol blue (Sigma). 
 Electrophoresis buffer 1x: 25mM Tris-HCl, 192mM Glycine (Serva), 1% SDS.  
 Transfer buffer: 25mM Tris, 190mM glycine, 20% methanol.  
 Bacteria Transformation by Heat Shock 
DNA constructs were amplified through transformation of chemically competent bacteria (E.coli 
TOP10R, Invitrogen) by heat shock. All the procedure was carried near the Bunsen flame to avoid 
contaminations. Bacterial competent cells stored in 100μL aliquots at -80ºC were thawed in ice 
for 10 minutes. 0.50µL of DNA preparation was added to the cells and maintained in ice for 30 
minutes. The thermal shock was carried out by incubating the tube at 42ºC for 90 seconds. 900µL 
of liquid LB medium (Miller's LB Broth, Conda) was then added and the mix was homogenized 
in the shaker at 37ºC for 1 hour. This allows cells to start expressing the plasmid encoded genes, 
including the antibiotic resistance. In order to concentrate the grown bacteria, the culture was 
centrifuged at 3000rpm for 5 minutes, and 800µL of supernatant was discarded. Cells were 
resuspended in the remaining supernatant and seeded in LB‐agar (Miller's LB Broth, Conda), agar 
(Panreac) plate (Nunc) with the pertinent antibiotic, previously warmed at 37ºC. Cells were 
incubated at 37ºC overnight. Only transformed cells - containing the plasmid and thus the 
resistance to the antibiotic - were supposed to grow. Once transformed bacteria were grown, 
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colonies were picked and individually cultured in 3mL of liquid LB medium with antibiotic. 
These pre-cultures were incubated at 37ºC overnight in the shaker. 
 Minipreparations of plasmidic DNA  
DNA minipreparations were performed to obtain plasmidic DNA by alkaline lysis of a bacterial 
pre-culture. This method provides low amounts of plasmidic DNA (5-15μg) with low purity. 
Nevertheless, it is enough for restriction-enzyme digestions carried out for plasmid verification.  
1.5mL of bacteria culture was centrifuged at 12,000g for 1 minute. Supernatant was discarded 
and cells were suspended in 200μL of P1 (resuspension buffer). 400μL of P2 was then added and 
incubated at room temperature for 5 minutes, in order to lyse cells. 400μL of P3 was added in ice 
for neutralizing the mix and for protein precipitation. After centrifuging at 12000g for 10 minutes, 
supernatant was recovered and protein precipitate was discarded. DNA precipitation was achieved 
by adding 0.6 volumes (550µL) of isopropanol (Panreac), mixing, incubating at room temperature 
for 5 minutes and finally centrifuging at 9000g for 10 minutes. Supernatant was discarded and 
DNA pellet was washed with 500μL ethanol (Panreac) 70% v/v. After centrifugation at 12,000g 
for 5 minutes, supernatant was discarded and the pellet was dried until the remaining ethanol was 
evaporated. Finally, the DNA pellet is resuspended in 30μL of milliQ water with RNAseA 
(QIAGEN).  
 Maxipreparations of plasmidic DNA 
DNA maxipreparations were performed to obtain large amounts of high-quality plasmidic DNA 
(250-1000mg). 200μL of transformed cultured bacteria were inoculated in a higher volume 
(250mL) of liquid LB medium with the pertinent antibiotic and grown in the shaker at 37ºC 
overnight. The DNA extraction was then carried out using the kit E.Z.N.ATM Fastifilter (Omega 
Bio-Tek), following the manufacturer’s instructions. In short, this method is based in the alcaline 
lysis of cells with potassium acetate solution. DNA is purified by ionic exchange chromatography 
and precipitated with isopropanol. The purified DNA is resuspended in 500μL of milliQ water 
and concentration was determined by spectrophotometry (section 8.1).  
 Restriction enzyme digestions 
Enzymatic digestions of DNA were performed using restriction endonucleases manufactured by 
Fermentas and/or New England Biolabs. Between 1 and 10 units (U) of restriction enzyme were 
used to digest 1 to 2 μg of plasmidic DNA, adding the buffer recommended by the manufacturer. 
Autoclaved milliQ water was added to reach the final volume fixed. For digestion reaction, 
Epperdorf tubes containing this mix were incubated at 37ºC, overnight. 
 DNA electrophoresis in agarose gel 
3.11.1. Agarose gel preparation 
Agarose 1% (w/v) gels were prepared in an Erlenmeyer flask by dissolving  1.80g of agarose 
(Seaken LE Agarose, Iberlabo) in 180mL of TAE 1x, heating the mix in a microwave. RedSafeTM 
Nucleic Acid Staining Solution 20.000x (iNtRON Biotechnology) was added to the flask when 
the agarose solution was tempered. RedSafeTM emits green fluorescence when it binds to DNA, 
becoming a non-carcinogenic alternative to ethidium bromide staining, typically used for DNA 
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display.  The solution was then poured into the gel tray (BioRad), and once the gel polymerized, 
the comb was removed.  
3.11.2. DNA electrophoresis 
The agarose gel was placed into the electrophoresis cuvette and covered by TAE 1x solution. 
Loading buffer 10x was added to the DNA samples, and each one was loaded inside a gel well, 
leaving one well for the DNA Ladder (GeneRuler 1kb, ThermoFisher Scientific). An electric 
current of 70-100 V was applied for 45-60 minutes (Sources of Power Pac Basic electrophoresis, 
BioRad). The gel was then placed in a UV transiluminator (GeneGenius BioImaging System, 
Syngene) to display separated DNA fragments, and images were captured with the GeneSnap 
software (Syngene). 
  DNA purification from agarose gel 
DNA fragments separated by electrophoresis were purified from agarose gels using the 
GENECLEAN® Turbo Kit (Q-BIOgene) following the protocol supplied by the manufacturer. 
This method is based on the ability of DNA to bind to a silica matrix. Purified DNA is finally 
suspended 30μL of nuclease free water (provided by the kit).  
 DNA defosforilation  
In order to avoid that linealized pGV vector was recircularized because of 5’ - 3’ ends relegation, 
they were defosforilated using a Thermosensitive Alkaline Phosphatase. 1U of FastAPTM 
(Fermentas) and the buffer recommended by the manufacturer (Buffer FastAP 10x, Fermentas) 
were added to the purified pGV linealized vector and incubated at 37ºC for 10 minutes. After that, 
enzymes were inactivated at 75°C for 5 minutes. 
 DNA quantification  
3.14.1. NanoDrop 
Plasmidic DNA obtained from mini and maxipreparations was quantified by UV absorption at 
a wavelength of 260nm (OD260/280). 2µl of the DNA preparation were loaded in the 
spectrophotometer NanoDrop ND-1000 (Thermo Scientific), which provides DNA purity and 
concentration in ng/μL. 
3.14.2. Agarose gel Electrophoresis 
Digested gel-purified DNA solutions were approximately quantified by electrophoresis in 1% 
agarose gel. 1μL of loading buffer was added to a volume of 6μL of DNA preparation, and then 
loaded into a gel well. 6μL of DNA Ladder GeneRuler 1kb (ThermoFisher Scientific) was 
loaded into an adjacent well. After electrophoresis, each DNA band was compared to the nearest 
band of the ladder, as they molecular length would be similar, thus the amount of retained dye 
would be comparable (the longer is a dsDNA molecule, the more dye is retained). The 
relationship of intensity between both bands is visually estimated, and the DNA concentration 
is calculated taking into account the ladder band concentration provided in the manufacturer’s 
reference.  
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 Ligation reaction  
Ligation reaction to clone the insert (hKLS) into the expression plasmid (pGV) was catalyzed by 
the T4DNA ligase (New England Biolabs). This enzyme allows to bind DNA fragments with 
cohesive or blunt ends, by catalyzing the formation of two covalent phosphodiester bonds 
between 3' hydroxyl ends of one nucleotide with the 5' phosphate end of another, in an  
ATP-dependent manner. Ligation solutions were prepared in a total volume of 15μL, using 10U 
of ligase, ligase buffer 10x and 20ng of pGV vector. The final volume was reached by adding 
milliQ water. Ligation reactions took place at 16ºC, overnight. Enzymes were then inactivated at 
65°C for 20 minutes. 
 Transient Transfection of HEK-293 cells with PEI 
There are several procedures by which DNA can be introduced into a host cell. The chosen 
method was transient transfection with polyethylenimine (PEI), a stable cationic polymer that 
condenses DNA into positively charged particles that bind to anionic cell surfaces. Consequently, 
the DNA:PEI complex is endocytosed by the cells and the DNA is released into the cytoplasm 
(Sonawane, Szoka, & Verkman, 2003). This way, it is achieved the transient genetic expression 
based on episomal plasmid DNA expression, whose product is harvested after 48-72 hours post 
transfection.  
Transfection of the expression vector was carried out in HEK-293 QB cells (ATCC® CRL-
573TM, Q-BIOgene) in 6-well plates. To achieve an efficient transfection, cells must be in  
50-70% confluence, so they were cultured the day before transfection in growth medium 
(DMEM) (Labclinics), supplemented with 10% (v/v) of FBS (Labclinics) and 1% (v/v) of 
antibiotics Penicillin/Streptomycin (Labclinics).  
For one well (1,2x106 cells), 6μg of plasmidic DNA were transfected. To this end, two different 
solutions were previously prepared in excess.  
 On one hand, 15μg of plasmidic DNA were dissolved in 300μL of NaCl 0.9% (B.Braun).  
 In a different tube, PEI 10mM (PolyScience) was mixed in NaCl 0.9% (using 2.25μL of PEI 
per μg of DNA) in a final volume equal to that of the DNA solution (300μL).  
 
In order to get the DNA:PEI complexes formed, the PEI solution was carefully added, drop by 
drop, into the DNA tube and incubated at room temperature for 20 minutes. Culture medium was 
then aspirated and transfection medium (DMEM + 1% FBS, without antibiotics) was added to the 
cultured cells (500μL per well). After that, the DNA:PEI mix was added (240μL per well) and 
plates were incubated at 37ºC and 5% CO2 for 3 hours. To avoid PEI-related toxicity, the medium 
was removed and growth medium was added. Plates were incubated at 37ºC and 5% CO2 for 72 
hours to let the plasmid be expressed inside cells, thus producing the coded protein. 
In order to ensure sterility, all the experiments using cell cultures were carried out in level 2 
biosafety laboratories, using a laminar flow cabinet with UV light system (Telstar). 
 Protein extraction  
Proteins produced by HEK-293QB transfected cells were extracted by cell lysis using RIPA 
buffer and a sonicator VCX130PB 130 watts (Sonics, Newtown, USA). Samples were kept in ice 
during every stage of the process in order to preserve protein integrity. 500μL of RIPA buffer was 
added to each cell sample (composed of cell extracts from 2 wells of similar conditions). Then 
cell samples were sonicated in three cycles. Each cycle consisted on 3 pulses of 3 seconds of 
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sonication at 40 kHz. Lysed cells were centrifuged for 15 minutes at 13200 rpm and 4ºC. 
Supernatant was transferred into a new Eppendor tube and stored at -20ºC until protein 
quantification.  
 Protein quantification  
Protein extracts were quantified through the Bradford's method (Bradford, 1976) using the Pierce 
BCA Protein Assay Kit (Thermo Scientific), which is a colorimetric assay based on the biuret 
reaction (reduction of Cu+2 to Cu+1 by protein) and the detection of Cu+1 using a bicinchoninic 
acid (BCA). This complex formed exhibits a strong absorbance at 562nm that is nearly linear with 
increasing protein concentrations over a broad working range (20-2000µg/mL). Protein 
concentrations are determined using a reference to standards of a common protein, bovine serum 
albumin (BSA) and spectrophotometry. In order to establish the standard curve, serial dilutions 
of BSA stock solution 2mg/mL (supplied by the kit) were prepared using milliQ water, consisting 
on final BCA concentrations of 0 – 1500 – 1000 – 750 – 500 – 250 - 125 - 25 - 0 (blank) µg/mL.  
Protein samples were diluted in milliQ water at 1:5, which is a suitable dilution for quantification 
of protein produced by cultured cells. Protein samples and standard solutions were loaded into a 
96-well microplate, per duplicate (10µL per well). 200µL of working solution (supplied by the 
kit) was added to each well. The microplate was then incubated for 30 minutes at 37ºC. 
Absorbance at 562nm was determined by the Absorbance Reader ELx808 (BioTek) and analyzed 
using the KC4 software (BioTek). 
 Protein analysis by Western Blot 
3.19.1. Protein sample preparation 
A volume of protein solution containing 15µug of protein extract (based on the measured 
concentration) was mixed with 5uL of loading buffer 6x, and milliQ water was added to reach a 
final volume of 30µL. Proteins were denatured at 99ºC for 10 minutes (Eppendorf Thermomixer 
R 5355 w/ MTP Microplate Thermoblock Heater Mixer Shaker, BioRad), and stored at -20ºC. 
3.19.2. Protein Electrophoresis in denaturing Polyacrylamide Gel  
The proteins contained in each sample were separated according to their molecular weight 
through sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). SDS is an 
anionic detergent that denatures proteins, which lose their three-dimensional structure. Then, 
when applying and electric field, proteins migrate according to their molecular weight.  
Gels for protein separation were prepared at 10% acrylamide in resolving gel buffer. A stacking 
gel at 5% acrylamide was prepared using stacking gel buffer. This is the part of the gel in which 
wells are formed, and allows protein concentration in the well prior to separation. For gel 
polymerization, APS 10% (Amresco) and terametil‐etilen‐diamina (TEMED) (Sigma), at 5:1 
proportion, were added to both solutions. 
Polymerized gel was placed into the electrophoresis chamber Mini Protean Tetra Cell (BioRad), 
and totally covered with electrophoresis buffer 1x. 30µL of protein sample was loaded in each 
gel well using a Hamilton syringe (Hamilton MicroliterTM Syringes, Hamilton). In order to 
identify each protein band according to its size, the molecular weight marker Page‐Ruler 
Prestained Protein Ladder (Fermentas) was loaded into a different well.  
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Protein samples were run in two cycles: first at 90V for 20 minutes (to concentrate proteins in 
the wells before entering into the separating gel fraction) and then at 130V for 1h30min (for 
protein separation), using the PowerPac Basic Power Supply (BioRad). 
3.19.3. Transference 
Once proteins were separated in the gel, they were transferred onto a PVDF blotting membrane 
(GE Healthcare Life Sciences). This membrane was previously activated with methanol HPLC 
grade (Sigma) during 10 seconds, washed with distilled water and then maintained in transfer 
buffer. Two Whatman papers (Extra Thick Western Blotting Filter Paper, Thermo Scientific) 
and the gel containing the separated proteins were wetted in transfer buffer for 15 minutes before 
transference. All components were placed on the transference device (Bio-Rad Trans-Blot SD 
Semi-Dry Transfer Cell, BioRad), in this order: one Whatman paper, the activated PVDF 
membrane, the gel containing the separated proteins and finally the second Whatman paper. A 
pin was rolled after placing every layer to eliminate bubbles that could alter the electric current, 
thus affecting the correct protein transference to the membrane. The transference was carried 
out by applying an electric current of 30V for 45 minutes.  
3.19.4. Immunodetection 
 Blocking 
In order to avoid unspecific bindings of the primary antibody, the transferred membrane was 
blocked in blocking solution (5% w/w BSA in TBST buffer), during 1h30min at room 
temperature in a shaker.  
 Primary antibody incubation 
The primary antibody (K-18.2) used in this experiments to recognise the hKLS protein had 
been designed by our group and produced by EZBiolab (Carmel, USA) on rabbits. Lyophilized 
antibody was reconstituted in a final volume of 25mL using ultrapure water (Braun) and stored 
in aliquots of 100µL and 1mL at -20ºC.  
Antibody dilutions were prepared with 5% BSA blocking solution, and used for membrane 
incubation at 4ºC overnight in gently agitation.   
After incubation, the antibody solution was recovered and the membrane was washed in TBST 
solution undergoing three fast washes followed by one 10-minute wash and three rounds of  
5-minute washes in a shaker. 
 Secondary antibody incubation 
Washed membranes were incubated for 1 hour at room temperature with the secondary 
antibody (Polyclonal Swine Anti‐Rabbit Ig/HRP, Dako Cytomation), diluted 1:10000 in 5% 
BSA. This is an anti-rabbit antibody conjugated to the peroxidase enzyme (HRP) that allows 
specific protein detection. After incubation, the membrane was washed using TBST solution, 
undergoing 2 fast washes and 3 rounds of 12-minute washes in a shaker.  
 Signal detection 
In order to detect the specific recognition of the protein of interest by the primary antibody, the 
membrane was incubated for 5 minutes with horseradish peroxidase-luminol reagents of 
ImmobilonTM Western Chemi-luminiscent HRP Substrate (Millipore): HRP Substrate Peroxide 
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Solution and HRP Substrate Luminol Reagent, previously mixed 1:1. The peroxidase enzyme 
conjugated to the secondary antibody catalyzed luminol oxidation by the peroxide, and 
oxidized luminol emitted light that was detected through a chemiluminiscence system 
(ChemiDoc, BioRad). Images were obtained and analyzed with QuantityOne 1-D analysis 
software from BioRad.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
19 
 
4. RESULTS AND DISCUSSION  
 pEX+hKLS plasmid amplification and verification 
The synthetic plasmid containing the hKLS gene (pEX+hKLS) was amplified by DNA 
maxipreparation after transformation of E.coli competent bacteria. Restriction digestions were 
performed using three specific endonucleases (PvuII, PstI) in order to ensure that the amplified 
DNA corresponded to the pEX+hKLS plasmid, whose digestion products were predicted using 
the program DNA Strider v1.4f4 for Macintosh (Table 1).  
For each digestion reaction, between 3 and 6 U of restriction enzyme were used to digest 1µg of 
DNA obtained from the maxipreparation, in a final volume of 20µL, under the conditions detailed 
in section 3.10. After restriction digestions, DNA fragments were separated by electrophoresis in 
agarose gel.  
As it can be observed in Figure 5, digestions using PvuII enzyme resulted in one DNA fragment 
above the 2500bp band of the marker and another at the level of 1000bp, in agreement with the 
2579bp and 1001bp expected fragments. Smaller expected bands (360 and 235bp) are not detected 
in this gel, as happens for the marker (bands smaller than 700bp are not visible). Despite PstI 
digestion was not completely effective, the expected bands of 2549bp and 1377bp can be 
identified in this picture. 
These results confirmed that the amplified plasmid was the pEX-hKLS, allowing us to go on with 
the cloning process. 
 
Table 1. Expected size of DNA fragments after digestion of pEX+hKLS plasmid with restriction enzymes 
(PvuII and PstI). DNA size measured in bp (base pairs).  
Enzyme PvuII PstI 
Expected DNA 
fragments (bp) 
2579 
1001 
360 
235 
2549 
1377 
249 
 
 
                             
Figure 5. Electrophoresis of DNA fragments resulting from digestion of amplified pEX+hKLS plasmid with 
PvuII and PstI enzymes. M: marker (DNA Ladder). 
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 hKLS cDNA isolation and pGV plasmid linearization     
Enzymatic digestions were then performed: 
a) to isolate the hKLS gene from the pEX+hKLS synthetic plasmid, and 
b) to linearize the pGV plasmid. 
 
The restriction enzymes used (Table 2) generate complementary ends, thus facilitating the 
binding between the hKLS fragment and the pGV linearized plasmid in the ligation reaction.   
Table 2. Restriction enzymes used to cleave each plasmid and expected DNA fragments generated. 
Plasmid Restriction enzymes Expected DNA 
fragments (bp) 
pEX+KLS XbaI + NotI 2492 
  1656 (hKLS insert) 
  15 
pGV NheI + NotI 4914 (linealized plasmid) 
  79 
 
After digestions, DNA fragments were separated by agarose gel electrophoresis (Figure 6). As 
shown in Figure 6.a, the hKLS insert (1656bp) could be identified above the level of 1500bp 
while the remainder pEX plasmid (2492bp) was around the level of 2500bp. The 15bp band 
expected from pEX+hKLS digestions was not visible due to its small length. Likewise, the pGV 
linearized plasmid (4914bp) was visible at the level of 5000bp (Figure 6.b), but the 79bp-band 
could not be identified.  
Bands belonging to the hKLS insert and the linearized pGV (marked in blue in figure) were 
isolated and purified from the gel following the protocol detailed in section 3.12).   
 
Figure 6. DNA fragments resulting from enzymatic digestions of pEH+KLS (a) and pGV (b) plasmids. 
The bands marked in blue correspond to the hKLS isolated cDNA (a) and the linealized pGV plasmid.  M: 
marker (DNA Ladder). 
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Linearized plasmids are prone to undergo re-circularization during ligation reaction when they 
have been previously digested with a single restriction enzyme, or with two enzymes with 
compatible ends. This was not supposed to be likely to happen in the pGV plasmid, given that its 
linearization had been done using two restriction enzymes (NheI and NotI) which do not generate 
complementary ends. However, partially-digested linear pGV plasmids could be present in the 
solution and spontaneously re-ligate during the ligation reaction. The resulting pGV  
re-circularized plasmid would highly decrease the efficiency of the hKLS-pGV ligation, and it 
would also give false positive colonies after bacteria transformation. To avoid this, the linearized 
pGV vector was dephosphorylated following purification from the agarose gel. 
 hKLS and pGV DNA quantification 
In order to fix the different conditions of the ligation reactions, hKLS and pGV concentrations 
had to be known. To this end, 6µL of each DNA solution were used to determine their 
concentration by electrophoresis in agarose gel (Figure 7), following the method detailed in 
section 3.14.2).  
The hKLS band showed approximately the double intensity than it nearest band of the ladder 
(1500bp; 10.00 ng/µL). Thus, the hKLS concentration in the solution was estimated to be about 
20 ng/µL. In the same way, the pGV band seemed to be four times more intense than the 6000bp 
ladder band (11.67 ng/µL), so the pGV concentration in its solution resulted in 46.67 ng/µL.  
 
Figure 7. Electrophoresis of hKLS and pGV DNA for quantification. 
Verification of pGV+hKLS ligation 
For the ligation reaction, different standard vector:insert proportions were tested: one containing 
equimolar amounts of both DNA fragments (1:1) and another with higher amount of insert (1:3). 
One reaction without insert (1:0) was used as a control of the phosphatase efficiency.  
Ligations were verified by transforming chemically competent bacteria. As expected, when 
seeded into LB-agar plates, only bacteria transformed with ligations 1:1 and 1:3 grew. 
Several colonies were picked from 1:1 and 1:3 plates and grown in liquid LB medium. Plasmidic 
DNA was extracted by minipreparation from every cultured colony and the correct orientation of 
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the insert into the vector was validated using specific restriction enzymes (Table 3) and 
electrophoresis in agarose gel (Figures 8 and 9).  
Plasmidic DNA extracted from colony 7 showed a positive result for both restriction reactions: 
Digestion using PvuII (Figure 8) produced a band at the level of 3500bp and another below 2500 
bp, which probably corresponded with the expected bands: 3639 and 2437 bp.  
Likewise, digestion with EcoICRI (Figure 9) resulted in a band between 6000 and 5000bp, 
feasibly corresponding to the expected band of 5831bp.   
Expected smaller bands were not visible in this gel. However, the presence of the previously cited 
bands, together with the absence of other exclusive bands expected from different constructs (for 
instance, 1362bp, 4892bp and/or 2579bp), provide enough evidence to confirm that the colony 7 
was transformed with the pGV+hKLS vector. 
Table 3. Expected DNA fragments (bp) obtained after restriction enzyme digestion (with PuvII and 
EcoICRI), depending on the DNA construct amplified: pGV+hKLS vector (positive result), pGV or pEX+hKLS 
(negative results). 
Enzyme pGV+hKLS  pGV  pEX+hKLS  
PvuII 3639 
2437 
502 
3639 
1362 
2579 
1001 
360 
235 
EcoICRI 5831 
507 
240 
4892 
109 
3935 
240 
 
 
 
Figure 8. DNA fragments resulting from digestion with PvuII enzyme. M: marker (DNA Ladder). 
 
 
Figure 9. DNA fragments resulting from digestion with EcoICRI enzyme. M: marker (DNA Ladder). 
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Then, with the aim of amplifying the pGV+hKLS plasmid, colony 7 was cultured in a higher 
volume of liquid LB medium. The plasmidic DNA was then extracted by maxipreparation and 
quantified using Nanodrop, resulting in 682.9 ng/µL. The obtained pGV+hKLS vector was 
sufficient for subsequent transfection in cultured mammalian cells, and for storage for future 
applications.  
Given the variety and importance of the future applications for the amplified vector, it was worth 
verifying the pGV+hKLS identity once again through a battery of different restriction enzyme 
digestions (Table 4) followed by electrophoresis in agarose gel. As it can be observed in Figure 
10, all expected bands beyond 352bp were clearly visible for the different restriction enzyme 
digestions, despite the bands of 352, 502 and 507bp expected from digestions with SnaBI, PvuII 
and EcoICRI, respectively. These are not easily identified in this picture due to its low quality, 
although they were detected in screen when the gel was analyzed in the UV transiluminator.  
Together, these results confirmed that the amplified plasmid corresponded to the pGV+hKLS, 
which could be used from this point onwards for different applications. 
 
Table 4. Expected DNA fragments (in bp) when digesting pGV+hKLS or pGV with different restriction 
enzymes.  
Enzymes XmaI SnaBI XmaI + SnaBI PvuII EcoICRI 
pGV+hKLS 3698 
1761 
1085 
7 
 
3974 
2252 
352 
3698 
1638 
610 
352 
123 
7 
3639 
2437 
502 
 
5831 
507 
240 
 
pGV 3698 
1273 
7 
3974 
675 
352 
 
3698 
675 
352 
123 
7 
3679 
1362 
 
4892 
109 
                             
Figure 10. Electrophoresis of DNA fragments resulting from verification digestions of the amplified 
vector. 
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 Transient transfection of HEK-293 cell line with the pGV+hKLS vector. 
Transfection is the process of introducing exogenous nucleic acids by non-viral methods into 
eukaryotic cells. With the aim of producing the hKLS protein in vitro, HEK-293QB cells were 
transfected with the expression vector pGV+hKLS through the PEI method. 
Apart from transfecting HEK-293QB cells with the pGV+hKLS vector (a), other different 
conditions were established as controls: 
(b) HEK-293QB cells transfected with the pGV plasmid, without genes cloned (pGV). 
(c) HEK-293QB cells transfected with the pDsRed2-Mito Vector, encoding the red fluorescent 
protein DsRed2 (pDsRed2-Mito). 
(d) HEK-293QB cells non-subjected to transfection procedure (NT). 
72 hours following transfection (time enough for the plasmids to be expressed), cells were 
observed in a Nikon fluorescence microscope connected to a camera (Digital Sight DS-U1, 
Nikon). Photographies of cells in plates (Figure 11) were taken in both clear field (1, upper row) 
and also using a red fluorescence filter (2, lower row). 
 
 
Figure 11. Photographies of cultured cells in clear field (1) and under a fluorescence filter (2).  
(a), (b) and (c) were transfected with pGV+hKLS, pGV and pDsRed2-Mito plasmids, respectively. (d): Non-
transfected cells (control). 
Cells non-subjected to the transfection procedure (d.1) were used to confirm that the culture 
conditions were suitable. In case of growth anomalies in the other conditions, these would be 
inherent to the transfection process.  
Cells transfected using the pDsRed2-Mito plasmid showed red fluorescence when the filter was 
applied (c.2), indicating that the transfection was effective and the introduced plasmid was being 
expressed.  
As expected, any other plate showed red fluorescence when the red filter was applied (a.1, b.2, 
and d.2), as none of them contained any gene coding for a fluorescent protein.  
The hKLS protein, coded in the pGV vector, did not appeared to be toxic for cells, as no 
differences in growth are observed in plate a.1 compared to the other conditions.  
Likewise, any toxicity related to the DsRed2 fluorescent protein was observed (c.1). 
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 Quantification of protein extracts from HEK-293 cells 
Once protein extracts were obtained from cultured cells, its concentration was determined using 
the BCA colorimetric assay and spectrophotometry, following the method explained in  
section 3.18.  
From the BSA dilutions of known concentration, a standard curve (Figure 12) was obtained with 
a R²=0.978, which implies the model is highly reliable. 
 
Figure 12. Standard curve of BSA for protein quantification. BSA standards of known concentration, 
ranging from 0 to 1500 µg/mL, are loaded (x-axis) and their absorbance at 562nm is measured (y-axis).  
 
The graph represents the absorbance value as the dependent variable (Y-axis) and concentration 
as the independent variable (X-axis), through the equation: 
y =  
𝑎−𝑑
1+(
𝑥
𝑐
)𝑏
+ 𝑑             (Equation 1) 
 
whose obtained parameters are shown in Table 5:  
Table 5. Standard curve fitting results. 
a b c d R R² Err. 
-0.014 1.184 1510.91 2.22 0.989 0.978 0.065 
 
Fitting the obtained parameters in Equation 1, Equation 2 is obtained and used to determine 
protein concentration (x) of an unknown sample by inserting the sample’s absorbance value (y) 
and solving for x.  
 
y =  
−2.234
1+(
𝑥
1510.91
)1.184
+ 2.22            (Equation 2) 
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Concentration of protein samples was calculated taking into account their dilution. The resulting 
value was obtained as the mean of the both replicas loaded for each sample (Mean column). 
 
Table 6. Protein concentration calculated for each cellular extract. 
Well ID Conc.\Dil. Concentrations Concentrations x Dil. 
Mean 
(µg/mL) 
Std Dev CV (%) 
pGV+hKLS 5 174.728 873.64 876.108 3.491 0.398 
(a)  175.715 878.576    
pGV 5 170.778 853.89 836.599 24.454 2.923 
(b)  163.861 819.307    
pDsRed2-Mito 5 165.838 829.191 794.56 48.976 6.164 
(c)  151.986 759.928    
Non transfected 5 159.906 799.53 802.002 3.497 0.436 
(d)  160.895 804.475    
 
Quantification of protein extracts reveals that there are not great differences in the protein 
production between the different conditions established. The transfected DNA construct and the 
protein produced do not seem to be toxic for cells, since its concentration is similar to that of the 
controls, as expected.  
 hKLS protein analysis by Western blot 
4.7.1. Optimization of K-18.2 antibody protocol using protein extracts from mice 
One of the main goals of this work was to get to analyze the hKLS protein obtained from human 
samples using the K-18.2 antibody, specially designed for it. As human samples are limited and 
highly valuable, and the K-18.2 antibody had never been used before, its optimal conditions 
were established using the mKLS protein, present in murine protein samples available in our 
laboratory.  
 Determining optimal antibody variant and dilution 
K-18.2 antibody was produced in two different rabbits (whose antibody extracts were named 
#1# and #2#, respectively). In order to determine which antibody variant was more specific for 
the KLS protein, they both were tested with brain protein extracts from three different mice.  
Ab K-18.2 from rabbit #1# recognized a protein at the level of about 20kDa, and the best 
dilution tested seemed to be the 1/5.000, as bands appeared more intense (Figure 13).  
In contrast, Ab K-18.2 from rabbit #2# revealed multiple bands of higher molecular weight 
(Figure 14). Of great relevance were the bands at the level of 55-50 kDa, as similar results 
were obtained in previous studies carried out by our group, using the antibody K-113, specific 
for the murine s-KL (mKLS) (R. Notario, personnal communication). As for the optimal 
dilution, it seemed to be the 1/10.000, given that at higher concentration, Ab K-18.2 from rabbit 
#2# revealed more background and unspecific bands.  
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Figure 13. mKLS immunodetection using variant #1# of K-18.2 antibody diluted 1/10.000, 1/5.000 
and 1/1000. 
 
Figure 14. mKLS immunodetection using variant #2# of K-18.2 antibody diluted 1/10.000, 1/5.000 
and 1/1000. 
 Evaluation of antibody specificity using an immunogenic peptide  
In order to check whether the K-18.2 antibody was specific for the recognized proteins, it was 
pre-incubated with an immunogenic peptide (provided by the antibody manufacturer). This 
immunogenic peptide is highly specific for the K-18.2 antibody and competes with the other 
proteins in the membrane for it.  
As Figure 15 shows, no protein in the membrane was recognized by the K-18.2 antibody, 
neither #1# nor #2#, indicating that both variants did not recognize unspecific proteins in 
previous experiments. In other words, the K-18.2 does not detect random proteins, but it is 
specific for its target, KLS. 
Therefore, since bands revealed by K-18.2 antibody from rabbit #2# seemed to be more prone 
to correspond to KLS, this variant was selected for the following experiments.  
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Figure 15. Specificity test for K-18.2 antibody (#1: left; #2#: right): Immunodetection of mKLS after 
pre-incubation with specific immunogenic peptide. 
 
 Background optimization for antibody K-18.2 #2#  
Once the best variant and dilution of the K-18.2 antibody were established, we went one step 
further with the aim of eliminating the background and unspecific signals detected. To this end, 
different washing conditions were tested after incubating the membrane with the K-18.2 #2# 
antibody, diluted 1/10.000. In all cases, 3 fast washes followed by one ten-minute wash in 
agitation were firstly performed. After that, different washing conditions were tested  
(Figure 16).  
 
Figure 16. Testing different washing conditions for antibody K-18.2 #2#. (a): 1 five-minute wash, (b): 
2 successive five-minute washes, (c): 3 successive five-minute washes. 
Even if it might not be clearly visible in this picture, condition (c) resulted to be the most 
suitable for background and unspecific signals elimination, and therefore, this was the protocol 
established in the following experiments.  
29 
 
4.7.2. Analysis of human KLS protein (hKLS) 
Once the optimal conditions for the K-18.2 antibody were established, Western Blot analysis 
were carried out using the human variant of the KLS protein (hKLS).   
 Analysis of the in vitro produced hKLS protein  
On the one hand, we used the protein extracted from pGV+hKLS-transfected cells to verify the 
hKLS production. As control, we used the protein extracted from cells transfected solely with 
the pGV plasmid. As Figure 17 shows, K-18.2 antibody recognised a prominent band at the 
level of 70kDa, which was not present in the pGV transfected cells. This, together with the fact 
that the molecular weight of the hKLS protein is 70kDa, indicates that this band corresponds 
to the hKLS protein. This experiment also revealed that the hKLS protein was highly produced 
by the transfected cells.  
 
Figure 17. Immunodetection of hKLS produced by transfected cells using the K-18.2 antibody. 
 Analysis of hKLS from human brain samples. 
On the other hand, protein extracts from human brains of both healthy and AD patients were 
analyzed using the K-18.2 antibody. These human brain samples were obtained from the 
biobanc of the Hospital de Bellvitge and processed in our laboratory to obtain the protein 
extracts.  
The antibody detected three bands of around 55kDa, 
both in healthy and AD patients (Figure 18). 
However, these do not fit the expected 70kDa band 
of the hKLS protein. This is in agreement with 
previous results obtained by our group in mice 
experiments: when analyzing Klotho from brain 
samples with different commercial antibodies, 
several bands smaller than 70kDa appeared as well. 
Conversely, when analyzing protein extracts from 
kidney, only one band was obtained. Thus, we 
believe that hKLS suffers some kind of processing 
in the brain, but further research is needed to confirm 
it. 
 
 
Figure 18. Immunodetection of hKLS 
extracted from healthy and AD 
human brains using the K-18.2 
antibody.  
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 Verification of K-18.2 specificity with human KLS 
In order to confirm that the previous bands were not random recognitions of the K-18.2 
antibody, the same protein extracts were analysed using the K-18.2 antibody pre-incubated 
with the immunogenic peptide. 
The membrane containing the protein extracts from both human patients and transfected  
HEK-293 cells did not show any band (Figure 19) , indicating that the proteins recognized by 
the antibody K-18.2 in the previous experiments were specific, likely corresponding to some 
form of hKLS. 
 
Figure 19. Testing K-18.2 specificity for human KLS obtained from brain samples (Healthy and AD) 
and HEK-293 transfected cells (pGV+hKLS and pGV). 
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5. CONCLUSION AND FUTURE APPROACHES 
In this work the human s-KL (hKLS) gene has been successfully cloned in a eukaryote expression 
vector (pGV) by means of Molecular Biology techniques. When transfecting the obtained 
construct (pGV+hKLS) into HEK-293 cultured cells, it was highly expressed and the stable 
protein of 70kDa hKLS was produced, as expected. This protein allowed the validation of the 
new K-18.2 antibody, specifically generated by our group to detect the human s-KL protein. Thus, 
this work has provided us two important tools to continue our research:  
 On the one hand, we have at our disposal the in vitro produced hKLS protein, which will 
be used to generate a calibration curve that allows the relative quantification of the protein 
extracted from human samples.  
 On the other hand, we have optimized the protocol of the K-18.2 antibody to detect the 
human s-KL protein by Western Blot. In the future, an ELISA assay will be set up to 
quantify also s-KL in low concentration samples, for instance in CSF.  
 
In this way, we will be able to correlate the levels of s-KL with the progression and severity of 
Alzheimer’s disease, as well as with aging.  
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